806 related articles for article (PubMed ID: 24492433)
1. The mechanism of action of BCG therapy for bladder cancer--a current perspective.
Redelman-Sidi G; Glickman MS; Bochner BH
Nat Rev Urol; 2014 Mar; 11(3):153-62. PubMed ID: 24492433
[TBL] [Abstract][Full Text] [Related]
2. Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder.
Kresowik TP; Griffith TS
Immunotherapy; 2009 Mar; 1(2):281-8. PubMed ID: 20046960
[TBL] [Abstract][Full Text] [Related]
3. Molecular networks discriminating mouse bladder responses to intravesical bacillus Calmette-Guerin (BCG), LPS, and TNF-alpha.
Saban MR; O'Donnell MA; Hurst RE; Wu XR; Simpson C; Dozmorov I; Davis C; Saban R
BMC Immunol; 2008 Feb; 9():4. PubMed ID: 18267009
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of cellular tumour rejection mechanisms in the peritumoral bladder wall after bacillus Calmette-Guérin treatment.
Saint F; Patard JJ; Groux Muscatelli B; Lefrere Belda MA; Gil Diez de Medina S; Abbou CC; Chopin DK
BJU Int; 2001 Oct; 88(6):602-10. PubMed ID: 11678759
[TBL] [Abstract][Full Text] [Related]
5. Bacillus Calmette-Guérin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections.
Larsen ES; Joensen UN; Poulsen AM; Goletti D; Johansen IS
APMIS; 2020 Feb; 128(2):92-103. PubMed ID: 31755155
[TBL] [Abstract][Full Text] [Related]
6. Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guérin-activated killer cells.
Brandau S; Suttmann H; Riemensberger J; Seitzer U; Arnold J; Durek C; Jocham D; Flad HD; Böhle A
Clin Cancer Res; 2000 Sep; 6(9):3729-38. PubMed ID: 10999767
[TBL] [Abstract][Full Text] [Related]
7. Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine.
Kawai K; Miyazaki J; Joraku A; Nishiyama H; Akaza H
Cancer Sci; 2013 Jan; 104(1):22-7. PubMed ID: 23181987
[TBL] [Abstract][Full Text] [Related]
8. Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy.
Chevalier MF; Schneider AK; Cesson V; Dartiguenave F; Lucca I; Jichlinski P; Nardelli-Haefliger D; Derré L
Eur Urol; 2018 Nov; 74(5):540-544. PubMed ID: 30033046
[TBL] [Abstract][Full Text] [Related]
9. Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L.
Kemp TJ; Ludwig AT; Earel JK; Moore JM; Vanoosten RL; Moses B; Leidal K; Nauseef WM; Griffith TS
Blood; 2005 Nov; 106(10):3474-82. PubMed ID: 16037389
[TBL] [Abstract][Full Text] [Related]
10. Role of urothelial cells in BCG immunotherapy for superficial bladder cancer.
Bevers RF; Kurth KH; Schamhart DH
Br J Cancer; 2004 Aug; 91(4):607-12. PubMed ID: 15266312
[TBL] [Abstract][Full Text] [Related]
11. Poly(I:C) potentiates Bacillus Calmette-Guérin immunotherapy for bladder cancer.
Ayari C; Besançon M; Bergeron A; LaRue H; Bussières V; Fradet Y
Cancer Immunol Immunother; 2016 Feb; 65(2):223-34. PubMed ID: 26759009
[TBL] [Abstract][Full Text] [Related]
12. Neutrophils and TRAIL: insights into BCG immunotherapy for bladder cancer.
Simons MP; Nauseef WM; Griffith TS
Immunol Res; 2007; 39(1-3):79-93. PubMed ID: 17917057
[TBL] [Abstract][Full Text] [Related]
13. Specific binding of bacillus Calmette-Guérin to urothelial tumor cells in vitro.
Schneider B; Thanhäuser A; Jocham D; Loppnow H; Vollmer E; Galle J; Flad HD; Ulmer AJ; Böhle A
World J Urol; 1994; 12(6):337-44. PubMed ID: 7881473
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives.
Zichi C; Tucci M; Leone G; Buttigliero C; Vignani F; Pignataro D; Scagliotti GV; Di Maio M
Biomed Res Int; 2017; 2017():5618174. PubMed ID: 28680882
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells.
Luo Y; Han R; Evanoff DP; Chen X
Clin Exp Immunol; 2010 Jun; 160(3):359-68. PubMed ID: 20148913
[TBL] [Abstract][Full Text] [Related]
16. Changes in mucosal immune cells of bladder tumor patient after BCG intravesical immunotherapy.
Chang SG; Lee SJ; Huh JS; Lee JH
Oncol Rep; 2001; 8(2):257-61. PubMed ID: 11182036
[TBL] [Abstract][Full Text] [Related]
17. Morphological aspects of the interaction of Bacillus Calmette-Guérin with urothelial bladder cells in vivo and in vitro: relevance for antitumor activity?
Teppema JS; de Boer EC; Steerenberg PA; van der Meijden AP
Urol Res; 1992; 20(3):219-28. PubMed ID: 1615584
[TBL] [Abstract][Full Text] [Related]
18. Cytological, histological, and clinical correlations in intravesical Bacillus Calmette-Guerin immunotherapy.
Bhan R; Pisharodi LR; Gudlaugsson E; Bedrossian C
Ann Diagn Pathol; 1998 Feb; 2(1):55-60. PubMed ID: 9845722
[TBL] [Abstract][Full Text] [Related]
19. Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion.
Gomes-Giacoia E; Miyake M; Goodison S; Sriharan A; Zhang G; You L; Egan JO; Rhode PR; Parker AS; Chai KX; Wong HC; Rosser CJ
PLoS One; 2014; 9(6):e96705. PubMed ID: 24896845
[TBL] [Abstract][Full Text] [Related]
20. Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response.
Kavoussi LR; Brown EJ; Ritchey JK; Ratliff TL
J Clin Invest; 1990 Jan; 85(1):62-7. PubMed ID: 2404029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
